Evidence map›Paper›PMID 36439130›Full record

ArticleFrontiers in immunology2022

Comparison of the frequency and phenotypic profile of

Elsa Du Bruyn, Sheena Ruzive, Patrick Howlett, Ashley J Jacobs, Cecilia S Lindestam Arlehamn, Alessandro Sette, Alan Sher, Katrin D Mayer-Barber, Daniel L Barber, Bongani Mayosi and 3 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 3 countries.

Elsa Du BruynWellcome Centre for Infectious Disease Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Sheena RuziveWellcome Centre for Infectious Disease Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Patrick HowlettWellcome Centre for Infectious Disease Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Ashley J JacobsWellcome Centre for Infectious Disease Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Cecilia S Lindestam ArlehamnCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, United States.
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, United States.
Alan SherImmunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Katrin D Mayer-BarberInflammation and Innate Immunity Unit, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Daniel L BarberT Lymphocyte Biology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Bongani MayosiDepartment of Medicine, University of Cape Town, Cape Town, South Africa.
Mpiko NtsekheWellcome Centre for Infectious Disease Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Robert J WilkinsonWellcome Centre for Infectious Disease Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Catherine RiouWellcome Centre for Infectious Disease Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
University of Cape Town · ZAWellcome Centre for Infectious Diseases Research in Africa · ZANational Institutes of Health · USLa Jolla Institute for Immunology · USNational Institute of Allergy and Infectious Diseases · USThe Francis Crick Institute · GBUniversity of California, San Diego · US

Funding

Inflammatory determinants of disease severity and treatment outcome in TB patientsU01AI115940 · NIAID · UNIVERSITY OF CAPE TOWN · PI SHER, ALAN, WILKINSON, ROBERT JOHN · 2015 to 2019
$1.1M
Influence of high-dose rifampin on Mycobacterial load and inflammatory mediators in pericardial TB patientsU01AI152103 · NIAID · UNIVERSITY OF CAPE TOWN · PI BARBER, DANIEL LEO, NTSEKHE, MPIKO · 2020 to 2025
$1000k
Contribution of the CD153/CD30 axis to Mycobacterium tuberculosis control in humansR21AI148027 · NIAID · UNIVERSITY OF CAPE TOWN · PI RIOU, CATHERINE · 2019 to 2020
$291k
NIAID NIH HHS R21 AI148027NIAID NIH HHS U01 AI115940NIAID NIH HHS U01 AI152103Wellcome Trust
6 · The paper itself

Abstract

Studies of the immune response at the site of disease in extra-pulmonary tuberculosis (EPTB) disease are scarce. In this study, we compared the cellular profile of

Indexed as

Mycobacterium tuberculosisTuberculosis, Lymph NodeCD4-Positive T-LymphocytesHumansInterleukin-2PhenotypeInterleukin-2CD4 responsepericardial fluidpericardial tuberculosissite of diseasetreatment responsewhole blood

Identifiers

PMID36439130
PMCPMC9692124
OpenAlexW4308939577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.